Olon Presents Olon Biotech, A New Division Operating by Biotechnological Processes

July 11th, 2022, Milan (Italy) – Olon is glad to present its new division. Olon Biotech, a division of Olon, focuses on biotechnological processes and offers Contract Development and Manufacturing Services (CDMO), as well as developing, manufacturing and selling Proprietary Products (PP) supporting customer companies in a wide range of industries, focusing on health & pharma, food, cosmetics, F&F and many others.

Olon Biotech represents an international leader in applied biotechnology to industrialization, able to manage the strong complexity implied in the tech transfer and in the scale up of biotech process.

At the heart of Olon Biotech are the two bio-hubs based in Settimo Torinese and Capua, Italy. The Biotech Centers are multipurpose and can handle production process with high level of complexity. They boast unparalleled flexibility and diverse capabilities thanks to the competencies acquired by applying different manufacturing processes to different products.

In the last five years, Olon has invested a total of over 80 million Euro in our Biotech Centers. The investments have generated a significant increase of our capacity, new purifications departments, some of which from greenfield investments, modernization and upgrading of existing areas, further than improvement and efficiency enhancement of production processes.

The investments made sites more sustainable, reduced their environmental impact and invested in skills and qualified experts: in the last five years, the number of people working in bio-hubs rose from 500 to 675

With more than 50 years of experience, Olon Biotech represents one the most extensive know how of microbial fermentation applied to CDMO and Proprietary Product production, including High Potent or Toxic Compound thanks to high containment systems.

Olon Biotech experience in fermentation embraces managing broad range of microorganisms as bacteria, yeast and fungi. It offers a strong expertise from small to large molecules – peptides, enzymes, proteins - always driven by customer focused attitude.

Media contact
Sabrina Spina
sspina@olonspa.it – mobile 338.6674289

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.


Olon Group is a global leader in the development and production of active pharmaceutical ingredients for CDMO and Generics, a reliable and preferential partner to the pharmaceutical, biotech, and specialty ingredients markets. With a 2021’s turnover of 580 Mio$, OLON supplies 300 APIs for the Generic market.

Thanks to all the 2.300 employees, and to highly qualified R&D team – more than 300 people – OLON can offer complete integrated packages and services to support the full development of APIs based on strong knowledge in both Chemical and Biological process, all of them under a full cGMP and regulatory coverage – holder of about 160 active US DMFs and 79 granted CoS.

Headquartered in Rodano (Milan, Italy), OLON has 11 manufacturing facilities - 8 located in Italy, 1 in Spain, 1 in USA and 1 in India, designed in compliance with the strictest international requirements, and 3 branch offices in Hamburg (Germany), Florham Park NJ (USA) and Shanghai (China). www.olonspa.com /